Arcutis Biotherapeutics, Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co, a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), announced that the companies have entered into a strategic… read more.
Bristol Myers Squibb has launched Clear Understanding, a campaign featuring patients living with moderate to severe plaque psoriasis who are sharing what it’s really like for them to… read more.
Skin, the largest organ of the human body, is home to a vast array of bacteria, fungi, and viruses – microorganisms that compose the skin microbiota. Among other… read more.
More than eight million people in the U.S. experience psoriasis, a condition in which skin cells build up and form itchy dry patches. A person’s vitamin D levels… read more.
Verrica Pharmaceuticals Inc. ,a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced FDA approval of Ycanth (cantharidin) topical solution for the treatment of molluscum… read more.
Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase III TRuE-AD3 study evaluating the safety and efficacy of Opzelura (ruxolitinib cream) in children (age at least… read more.
The combination of curettage and cryosurgery is a safe and effective treatment method for the most common form of skin cancer, basal cell carcinoma. A study from the… read more.
GSK plc announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved an updated indication for Shingrix (Recombinant Zoster Vaccine, Adjuvanted – RZV) for the… read more.
UCB, a global biopharmaceutical company,announced that the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis remains under review with… read more.
The FDA recently approved the Janus kinase (JAK) inhibitor ritlecitinib (Litfulo) for adults and adolescents with severe alopecia areata. It is, so far, the only treatment approved by the FDA… read more.
Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to… read more.
Beneath and beyond the reddish, flaky lesions that form in the skin of those with psoriasis, mild and severe forms of the disease can be told apart by… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
